What happened
There is now a registered Phase 2a trial testing MOTS-c in people. It is randomized, double-blind and placebo-controlled, it is recruiting, and according to its ClinicalTrials.gov record it began dosing on February 2, 2026.
If you have read anything about MOTS-c in the last few years, you know why that matters. The standing criticism of this peptide has always been the same one sentence: the metabolic findings are real but they are almost entirely from mice and cell cultures, and nobody has tested whether any of it holds up in a human body. That sentence is now, finally, starting to change.
Here is the trial, from the registry entry itself.
| Detail | What the registry says |
|---|---|
| Registry ID | NCT07505745, acronym MOTS-MET |
| Design | Phase 2a, randomized 1:1, placebo-controlled, quadruple-blinded |
| Sponsor | Hudson Biotech (industry) |
| Enrollment | 120 participants, estimated |
| Population | Adults 18 to 65, BMI 27 to 40, with prediabetes |
| Dosing | Fixed dose, once daily subcutaneous injection, 12 weeks |
| Primary measures | Change in insulin sensitivity (Matsuda Index from a 75 g glucose tolerance test), plus treatment-emergent adverse events |
| Sites | One listed: Peking University Shenzhen Hospital, Shenzhen, China |
| Primary completion | Estimated February 2027 |
Why this is a real milestone
Before this, the closest thing to human MOTS-c data was CB4211, a MOTS-c analogue developed by CohBar. It cleared Phase 1a/1b for safety and tolerability, and reporting at the time indicated development was subsequently discontinued. An analogue is a modified molecule, not the peptide itself, so even that only told you so much.
MOTS-MET is different in a way that counts. It is testing native MOTS-c, against placebo, with blinded outcome assessors and an independent data monitoring committee, and its primary endpoint is an actual efficacy measure rather than just safety. The Matsuda Index is a standard, respectable way to quantify insulin sensitivity from a glucose tolerance test. Whatever the result turns out to be, it will be the first time anyone can point to a controlled human answer on the central claim made for this peptide.
Now the part the marketing is skipping
You are going to see this trial cited in a lot of sales copy over the next few months, and some of that copy is already inaccurate. One press release circulating this month framed July as MOTS-c's "biggest month yet" on the strength of "the new human trial." The trial is not new as of July. The registry lists an actual start date in February and a first posting on April 1.
Four things about the design are worth holding onto, because they set the limits on what this study can tell you.
It is not a study of midlife women. Enrollment is open to all sexes, ages 18 to 65, selected on prediabetes and BMI rather than on menopausal status. Nothing in the registered design isolates perimenopausal or postmenopausal metabolism, and no results are broken out that way. The specific question most of our readers actually have is not the question being asked.
It excludes anyone on a GLP-1. Use of glucose-lowering medication within three months of screening, including GLP-1 receptor agonists, metformin and SGLT2 inhibitors, is an exclusion criterion. So this will not tell you anything about how MOTS-c behaves alongside semaglutide or tirzepatide.
It is small, single-site and industry-sponsored. One hundred twenty participants at one hospital, funded by the company with an interest in the outcome. That is an entirely normal shape for Phase 2a. It is also why Phase 2a results get replicated before anyone calls them settled.
The registry lists it as not FDA-regulated. The record marks the drug as not FDA-regulated, and the listed site is in China. This is not a study running under FDA oversight toward a US approval.
When you can expect to know anything
Primary completion is estimated for February 2027, with full study completion estimated for May 2028. Registry dates move, and they usually move later rather than earlier. Realistically you are waiting more than a year for a first look at the data, and longer for peer-reviewed publication.
So the honest status of MOTS-c today is unchanged from last month. The mechanism is genuinely interesting, the preclinical work on AMPK activation and glucose uptake in skeletal muscle is genuinely suggestive, the human efficacy evidence still does not exist yet, and a trial being underway is not the same as a trial having an answer. Anyone selling you MOTS-c on the strength of "it's in human trials now" is describing a hypothesis being tested, not a result.
What to do with this
If you were already looking at MOTS-c, this is a reason to keep watching rather than a reason to change what you are doing. Set a mental reminder for early 2027 and see what the Matsuda numbers say.
If you are buying it now, the variables you actually control are the same ones as always, and they have nothing to do with this trial. What are you paying per milligram, and can the vendor show you third-party testing for identity and purity on the specific lot. MOTS-c pricing spreads widely between vendors for what is nominally the same 16-amino-acid peptide, which is exactly the gap our price comparison tool exists to close. The vendor directory tracks who publishes testing and who does not.
We will cover the readout here when it lands.
Sources
- 1. "MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (MOTS-MET)," NCT07505745. ClinicalTrials.gov, U.S. National Library of Medicine. Record first posted April 1, 2026; status verified March 2026.
- 2. "MOTS-c Peptide: Science, Clinical Evidence and the July 2026 FDA PCAC Review." BSR Intelligence, 2026.
- 3. "CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211." CohBar, Inc., August 2021.